Amgen Reports real-world evidence Data for Fitusiran in Endometrial cancer

Amgen today announced real-world evidence results for Fitusiran in patients with Endometrial cancer. The study demonstrated that Fitusiran reduces biomarker levels substantially compared to standard of care or placebo. These results provide important insights into the treatment of Endometrial cancer and support the continued development of Fitusiran in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Fitusiran was consistent with previous observations, with no new safety signals identified.